Opinion on Pharmaceuticals

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Generics: making money by saving money

Global blockbusters worth $82 billion look set to lose US patent protection by 2007, creating an unprecedented growth opportunity for generics companies. As global cost containment drives regulatory reform, players such as Teva, Andrx and Ranbaxy are well positioned to capitalize on the new opportunities. Traditional pharma companies must not ignore this threat.

Published By Datamonitor
07 Aug 2002
CommentWire
CommentWire

Cipla: lobbying for more generics in South Africa

Generics maker Cipla is trying to cut a deal to supply South African mining firm Anglo American with HIV drugs. Employer provision of HIV medicine is gaining popularity in South Africa, and last year's court case created the opportunity for the government to license generic versions of patented drugs. However, it has so far been reluctant to use this power.

Published By Datamonitor
20 Aug 2002
CommentWire
CommentWire

Biotechnology: FDA rule changes could boost generics

The FDA's review of current good manufacturing practice (cGMP) seeks to improve standards of drug manufacture. At the same time, the regulations should reduce confusion over biotech-derived drug products. These changes may open the door to greater use of new manufacturing methods and long term, greater opportunities for biogenerics.

Published By Datamonitor
28 Aug 2002
CommentWire
CommentWire

Novartis: Eastern European generics to bring multiple rewards

Buying Slovenia's Lek gives an East European footing to Novartis' already large generics business. Lower R&D costs there should allow Novartis to move into the higher value specialty generics segment. The acquisition also gives Novartis revenues from generic Augmentin, which, unlike its own version of the product, are not dogged by risk of litigation.

Published By Datamonitor
04 Sep 2002
Expert View
Expert View

Cancer: the generic impact

The cancer market is set for a boom in low cost drugs, as a significant number of high value cancer drugs are set to lose patent protection over the next decade, triggering a dramatic influx of cheaper generic equivalents. But as patients and generics manufacturers bask in the glow, pharmaceutical companies will be forced to gamble on innovation for fear of being left out in the cold?<BR />

Published By Datamonitor
20 Sep 2002
CommentWire
CommentWire

Barr: taking the tamoxifen challenge

Barr says the FDA gave it permission to launch generic tamoxifen 10mg tablets starting August 20, 2002, but the agency now wants Barr to wait until February 2003. The cost to Barr of any delay will be heavy, particularly given its low margins - so it can be expected to fight fiercely. Any approval will be a blow to the drug's developer, AstraZeneca.

Published By Datamonitor
24 Sep 2002
CommentWire
CommentWire

Smallpox vaccination: planning to catch up

In response to the fear of bioterrorism, the US government has given states instructions on how to manage a smallpox outbreak. While the climate of worry over a biological attack has driven vaccine stockpiling - and useful revenues for pharma companies - the necessary strategy and infrastructure lags far behind.

Published By Datamonitor
27 Sep 2002
CommentWire
CommentWire

Barr/AstraZeneca: another tamoxifen stalemate

Although tamoxifen is a generic drug in most countries, it is still protected in the US. Under a 1992 agreement between AstraZeneca and Barr, generic competition should have begun in August - but additional pediatric indications have pushed it back to February 2003. Barr is suing AstraZeneca for the right to produce tamoxifen now; it's not clear who will be the victor.

Published By Datamonitor
10 Oct 2002
Expert View
Expert View

Biogenerics: the threat to protein manufacturers looms large

The therapeutic proteins market is becoming increasingly attractive to generic competitors, which pose a significant threat to the revenue streams of some of the most established classes. As generic manufacturers move in who stands to gain and will existing therapeutic protein manufacturers survive the competition?

Published By Datamonitor
11 Oct 2002
CommentWire
CommentWire

BMS: new Glucovance indication won't end decline

The FDA has approved the use of BMS' glyburide and metformin pill, Glucovance, alongside the TZD class of anti-diabetic medications. TZDs are commonly administered to patients who are not under adequate glycemic control. However, the approval is unlikely to have a significant impact - physicians are prescribing the drugs as a combination already.

Published By Datamonitor
16 Oct 2002

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.